Spots Global Cancer Trial Database for Phase II Study of BI 2536 in Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of BI 2536 in Prostate Cancer
Official Title: A Single Arm Phase II Study to Investigate the Efficacy, Safety and Pharmacokinetics of a Single Dose of 200 mg of i.v. BI 2536, Administered Once Every 3 Weeks in Patients With Advanced Metastatic Hormone-refractory Prostate Cancer.
Study ID: NCT00706498
Conditions
Interventions
Study Description
Brief Summary: A study to investigate the activity of BI 2536 in Prostate Cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
1216.19.4407 Boehringer Ingelheim Investigational Site, Cambridge, , United Kingdom
1216.19.4405 Boehringer Ingelheim Investigational Site, Guildford, , United Kingdom
1216.19.4402 Boehringer Ingelheim Investigational Site, Headington, , United Kingdom
1216.19.4406 The Christie NHS Foundation Trust, Manchester, , United Kingdom
1216.19.4404 Boehringer Ingelheim Investigational Site, Newcastle Upon Tyne, , United Kingdom
1216.19.4401 Boehringer Ingelheim Investigational Site, Sutton, , United Kingdom
Contact Details
Name: Boehringer Ingelheim
Affiliation: Boehringer Ingelheim
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
